Immunoglobulin E specific for Vespula pensylvanica venom allergens (sIgE (Vespula pensylvanica))

Immunoglobulin E (IgE) antibodies specific for Vespula pensylvanica (Western Yellowjacket) venom allergens are the primary mediators of Type I hypersensitivity reactions to yellowjacket stings [1]. These antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils; upon subsequent exposure to venom allergens such as Ves p 1 (phospholipase A1) or Ves p 5 (antigen 5), the IgE molecules are cross-linked, triggering the release of inflammatory mediators like histamine and leukotrienes [2, 3]. This process can lead to clinical symptoms ranging from localized swelling to life-threatening systemic anaphylaxis [4]. Therapeutic strategies targeting these specific IgE antibodies include the use of Omalizumab, a monoclonal antibody that sequesters free IgE, and venom immunotherapy (VIT), which aims to desensitize the patient by inducing immune tolerance and the production of protective IgG4 antibodies [5]. Monitoring the levels of these specific IgE antibodies is crucial for diagnosing venom allergy and assessing the risk of severe reactions in sensitized individuals [4]. References: [1] Golden DB. Immunol Allergy Clin North Am. 2006; [2] WHO/IUIS Allergen Nomenclature; [3] Galli SJ, et al. Nature. 2008; [4] Bilò MB, et al. Allergy. 2005; [5] Galera C, et al. J Allergy Clin Immunol. 2009.

Other names

Western yellowjacket venom-specific IgEVespula pensylvanica sIgEYellowjacket venom IgE

Omalizumab binds to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils [5]. Venom immunotherapy (VIT) works by inducing regulatory T cells and shifting the immune response from a Th2 to a Th1 profile, leading to the production of IgG4 blocking antibodies that compete with IgE for allergen binding [1].